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Abstract 
Background: Prostate cancer is the second most common reason of death in men. Multidisciplinary therapy is the 
best treatment option, although, there is no common consent on optimal therapy for advanced prostate cancer. Case 
Presentation: The present study reports a case of 75 year-old man who had a huge heterogeneous soft tissue mass 
lesion with non-homogeneous enhancement consisted low attenuated foci occupying pelvis cavity and lower 
abdomen with loss of mesenteric fat and invasion to posterior bladder wall due to T4N1Mx prostate cancer. The 
patient was treated with adjuvant radiotherapy (RT) plus local hyperthermia (HT).  Conclusion: This report shows 
the potential capability of HT application during RT. Radiotherapy with hyperthermia combination revealed a 
dramatic response in this case and after treatment it left the patient asymptomatic.  
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Prostate cancer is the most commonly 
identified malignant disease in men and microscopic 
prostate cancer will develop during their lifetime 
about 30%  (1). In patients with advanced and 
unresected prostate cancer, combination therapy is 
the best option for increasing life expectancy (2). A 
number of studies have shown that the simultaneous 
use of hyperthermia (HT) and radiotherapy (RT) is 
more effective in patients with huge mass prostate 
(3). However, there are few studies on radiotherapy 
combination with hyperthermia in patients with 
locally advanced and unresected prostate gland. To 
our best knowledge, the present study is the first 
report of the use of these two modalities combination 
for the treatment of locally advanced prostate cancer 
in Iran. 
Case Presentation 
Patient presentation   
A 75-year old man presented with a huge 
heterogeneous soft tissue mass of prostate cancer 
(T4N1Mx) in lower abdomino-pelvic area with loss of 
mesenteric fat and invasion to posterior bladder wall. 
Upon examination, the patient had a palpable 
abdominal mass that was the same size as the small 
ball. The CT scan imaging revealed a large 
heterogenous hyperintense mass originated from the 
prostate cancer (Fig. 1). In regard to the persistent 
symptoms, conservative treatment was chosen for this 
case. Symptoms in examination were: edema, large 
prostate, pelvic visceral invasion, urinary retention and 
pressure on the distal ends of the ureters. Patient 
treatment was continued for 33 days. 
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Radiotherapy 
Prior to radiotherapy, CT images were 
obtained for treatment planning and it revealed stable 
disease according to the response evaluation criteria 
in solid tumors. RT was routinely prescribed as a first 
treatment choice for this case. The patient received a 
three dimensional planned four-field box technique 
(15 MV photon beam Siemens linear accelerator) 
with external radiation fields to the pelvic at a dose 
of 4500 cGy for 25 fractions of 180 cGy. The clinical 
target volume (CTV) was defined as the persistent 
mass with an enough safe margin around it. RT was 
performed at the Omid Tehran Radiotherapy 
Oncology Clinics and continued over the treatment 
course. No chemotherapy was considered for this 
case and patient was under routine examinations 
during treatment.  
Hyperthermia treatment 
After evaluation of the CT images and careful 
clinical examination by the radiation oncologist, the 
criteria were checked for HT. Informed consent was 
obtained from the patient for hyperthermia 
procedure. Hyperthermia electrodes were positioned 
over the target volume according to the radiation 
treatment field marked on the patient skin. 
Hyperthermia regime is normally selected for two 
sessions per week over the whole radiotherapy 
course. There is an expert investigated HT protocol 
and evidences nearly for each part of the body and 
each session that we also used them for the present 
study. HT regime for this case was 2 sessions per 
week for 60 minutes in each session and overall 10 
sessions were administered to his lower abdomen and 
pelvic area as it is demonstrated in the Fig 2. The 
time gap between HT and RT was at least one hour 
either pre-RT or Post-RT. We used loco regional 
electric HT system (Celsius 42+ Co., Germany) that 
is operating at frequency of 13.56 MHZ. Machine 
has two sets of, namely, arm and bed electrodes. 
Heating is performed sequentially in each session 
and then for different sequence, energy parameters 
should be determined including electrode size, 
position, power (watt), time (minutes) and energy 
(Kilojoules).  After patient set up and selecting the 
energy parameters, HT procedure is started under 
direct control of the operator. For this palliative case 
HT was added to the conventional RT regime.  
Discussion 
In first examination, patient manifested with 
 
Fig. 1. CT scan of prostate cancer before treatment 
shows multi focal mass in the pelvic. The large 
tumor mass in the pelvic pushed the urinary bladder 
and rectum to the antero-lateral and Postero-lateral 
directions, respectively. Scale at the left side of the 
image reveals the size of the mass. 
 
Fig. 2. Patient position during treatment with 
hyperthermia system. Arm electrode with 25 cm 
diameter (arrow) and bed electrode (not shown) are 
placed on the anterior and posterior surfaces, 
respectively. 
 
Fig. 3. In the repeated CT image revealed the 
changes in tumor size and anatomic information. 
Antero-posterior diameter was dramatically 
decreased and pressure was removed from lympho-
vascular drainage system as well as on the ureters. 
Local hyperthermia case study                                                                                                            Khalafi et al. 
Vol 1, No 3,  Fall  2015 
c 
multiple symptoms and complication secondary to 
the large pelvic mass originated from prostate 
carcinoma. After termination of treatment period 
(including both RT and HT) patient was examined by 
the physician and control imaging was obtained with 
same protocol to the pre-treatment CT scan for 
evaluating response to treatment and measuring the 
changes in the tumor size.  
Dramatic response was observed following 25 
fractions RT combined with 10 sessions local HT. 
Two weeks after treatment termination, lower 
extremity lymphedema almost completely 
disappeared, pelvic pain was significantly reduced 
and urinary retention was also significantly better. 
The antero-posterior diameter of the mass was 
reduced to less than 1/3 of its initial size (tumor 
volumes were 633 and 138 cc before and after 
RT+HT, respectively). Bladder and rectum were 
displaced to their normal anatomic sites and all 
symptoms secondary to the pelvic mass were 
significantly reduced (Fig. 3).    
External HT is a noninvasive modality for 
delivering heat to the interested part of the body. 
Based on the patient’s tumor histopathology, local 
HT can be prescribed to the RT area as a 
complementary medicine. According to improved 
previous studies, hyperthermia can positively change 
the quality of life, biochemical recurrence and overall 
survival (4). 
Researchers who have used HT with RT agree 
that it does not increase complication which may be 
induced by RT alone (5). In patients with advanced 
prostate cancer, hyperthermia with radiotherapy may 
be safe and useful (6). Combination of radiotherapy 
and hyperthermia was practicable and effective for 
this case of advanced prostate adenocarcinoma in 
comparison to the previous RT alone cases. 
However, for prostate cancer, it has been revealed 
that the patients eligible for hyperthermia in 
combination with radiotherapy are those who are 
androgen resistant and hormone refractory, or have 
received a high dose of radiotherapy, or there is  a 
possibility to develop radiotoxicity to vital organs such 
as the rectum. In fact, all authors who have HT 
experience in association with radiotherapy confirm 
that HT does not impose any complication more than 
single radiotherapy method (5). 
To our best knowledge this is the first local 
regional prostate cancer hyperthermia case study in 
Iran which finds out a promising future in the 
treatment of not only the hormone refractory prostate 
cancers but also other types of malignancies.  
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